English  |  正體中文  |  简体中文  |  總筆數 :0  
造訪人次 :  52103231    線上人數 :  837
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

"tai w t"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 31-40 / 66 (共7頁)
<< < 1 2 3 4 5 6 7 > >>
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2021-07-03T03:34:25Z Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells Chen K.-F.; Lin J.-P.; Shiau C.-W.; Tai W.-T.; Liu C.-Y.; Yu H.-C.; PEI-JER CHEN; Cheng A.-L.
臺大學術典藏 2021-07-03T03:34:23Z Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells Tai W.-T.; Shiau C.-W.; Chen H.-L.; Liu C.-Y.; Lin C.-S.; Cheng A.-L.; PEI-JER CHEN; Chen K.-F.
臺大學術典藏 2021-07-03T03:34:22Z Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody Chen K.-F.; Chen H.-L.; Shiau C.-W.; Liu C.-Y.; Chu P.-Y.; Tai W.-T.; Ichikawa K.; PEI-JER CHEN; Cheng A.-L.
臺大學術典藏 2021-07-03T03:34:13Z SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model Tai W.-T.; Shiau C.-W.; Li Y.-S.; Chen Y.-L.; Chu P.-Y.; Huang J.-W.; Hsu C.-Y.; Hsu Y.-C.; PEI-JER CHEN; Chen K.-F.
臺大學術典藏 2021-07-03T03:34:12Z Discovery of novel src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma Tai W.-T.; Shiau C.-W.; PEI-JER CHEN; Chu P.-Y.; Huang H.-P.; Liu C.-Y.; Huang J.-W.; Chen K.-F.
臺大學術典藏 2021-07-03T03:33:59Z Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition Su T.-H.; Shiau C.-W.; Jao P.; Liu C.-H.; Liu C.-J.; Tai W.-T.; Jeng Y.-M.; Yang H.-C.; Tseng T.-C.; Huang H.-P.; Cheng H.-R.; PEI-JER CHEN; Chen K.-F.; Kao J.-H.; Chen D.-S.
臺大學術典藏 2021-07-03T03:33:49Z Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047)) Tai W.-T.; Cheng A.-L.; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN; Chen K.-F.
臺大學術典藏 2021-07-03T03:33:47Z Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2017) 66(3) (666–668) (S0168827816307127) (10.1016/j.jhep.2016.12.007)) Tai W.-T.; Cheng A.-L.; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN; Chen K.-F.
臺大學術典藏 2021-07-03T03:33:43Z Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis Su T.-H.; Shiau C.-W.; Jao P.; Yang N.-J.; Tai W.-T.; Liu C.-J.; Tseng T.-C.; Yang H.-C.; Liu C.-H.; Huang K.-W.; Hu T.-C.; Huang Y.-J.; Wu Y.-M.; Chen L.-J.; PEI-JER CHEN; Chen D.-S.; Chen K.-F.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:42Z Corrigendum to “Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity” (Eur. J. Med. Chem. (2012) 55 (220–227)(S0223523412004497)(10.1016/j.ejmech.2012.07.023)) Chen K.-F.; Tai W.-T.; Hsu C.-Y.; Huang J.-W.; Liu C.-Y.; PEI-JER CHEN; Kim I.; Shiau C.-W.

顯示項目 31-40 / 66 (共7頁)
<< < 1 2 3 4 5 6 7 > >>
每頁顯示[10|25|50]項目